key: cord-0330125-j1eenfdt authors: Saville, James W.; Mannar, Dhiraj; Zhu, Xing; Srivastava, Shanti S.; Berezuk, Alison M.; Demers, Jean-Philippe; Zhou, Steven; Tuttle, Katharine S.; Sekirov, Inna; Kim, Andrew; Li, Wei; Dimitrov, Dimiter S.; Subramaniam, Sriram title: Structural and Biochemical Rationale for Enhanced Spike Protein Fitness in Delta and Kappa SARS-CoV-2 Variants date: 2021-09-02 journal: bioRxiv DOI: 10.1101/2021.09.02.458774 sha: 11323453b20c554942959efa96397e1c6a6789c0 doc_id: 330125 cord_uid: j1eenfdt The Delta and Kappa variants of SARS-CoV-2 co-emerged in India in late 2020, with the Delta variant underlying the resurgence of COVID-19, even in countries with high vaccination rates. In this study, we assess structural and biochemical aspects of viral fitness for these two variants using cryo-electron microscopy (cryo-EM), ACE2-binding and antibody neutralization analyses. Both variants demonstrate escape of antibodies targeting the N-terminal domain, an important immune hotspot for neutralizing epitopes. Compared to wild-type and Kappa lineages, Delta variant spike proteins show modest increase in ACE2 affinity, likely due to enhanced electrostatic complementarity at the RBD-ACE2 interface, which we characterize by cryo-EM. Unexpectedly, Kappa variant spike trimers form a novel head-to-head dimer-of-trimers assembly, which we demonstrate is a result of the E484Q mutation. The combination of increased antibody escape and enhanced ACE2 binding provides an explanation, in part, for the rapid global dominance of the Delta variant. . 3 l i n e a g e f r e q u e n c y i n I n d i a f r o m J a n u a r y t o J u l y 2 0 2 1 . D e p o s i t e d s e q u e n c e s w e r e d o w n l o a d e d f r o m t h e G I S A I D i n i t i a t i v e . T h e 9 5 % c o n f i d e n c e i n t e r v a l i s p l o t t e d a s t h e l i g h t e r s h a d e d b o r d e r a r o u n d e a c h l i n e . T h i s f i g u r e p a n e l w a s g e n e r a t e d u s i n g t h e o u t b r e a k . i n f o p r o j e c t 3 . ( B ) D a i l y c o n f i r m e d C O V I D 1 9 c a s e s i n I n d i a a s c u r a t e d b y t h e o u t b r e a k . n o a c i d s e q u e n c e b o x p l o t s f o r t h e w i l d -t y p e ( D 6 1 4 G ) a n d B . 1 . 6 1 7 s u b -l i n e a g e s . T h e a b b r e v i a t i o n s a r e N T D : N -t e r m i n a l d o m a i n , R B D : R e c e p t o r -b i n d i n g d o m a i n , a n d R B M : R e c e p t o r a l p r e v a l e n c e f o r t h e A l p h a , B e t a , G a m m a , a n d D e l t a l i n e a g e s o f S A R S -C o V -2 f r o m J a n u a r y t o J u l y 2 0 2 1 . T h e s e q u e n c e d a t a w e r e d o w n l o a d e d f r o m t h e G I S A I D i n i t i a t i v e a n d p l o t t e d a s t h e p e r c e n t a g e o f t h e g l o b a l p r e v a l e n c e f o r e a c h w e e k 1 , 2 . R e s u l t s A n t i b o d y E v a s i o n b y D e l t a a n d K a p p a S p i k e p r o t e i n s T o a s s e s s t h e a n t i b o d y e v a s i v e p r o p e r t i e s o f t h e K a p p a a n d D e l t a s p i k e p r o t e i n m u t a t i o n s , w e p e r f o r m e d a n t i b o d y b i n d i n g a n d n e u t r a l i z a t i o n s t u d i e s u s i n g p u r i f i e d v a r i a n t s p i k e e c t o d o m a i n s ( F i g u r e S 1 ) a n d v a r i a n t p s e u d o -t y p e d v i r u s e s r e s p e c t i v e l y . F i r . . C r y o -E M S t r u c t u r e o f t h e K a p p a V a r i a n t S P r o t e i n R e v e a l s a H e a d -t o -H e a d D i m e r i z a t i o n P h e n o m e n o n W e n e x t a i m e d t o e v a l u a t e t h e e f f e c t o f K a p p a a n d D e l t a S p r o t e i n m u t a t i o n s o n s T h e K a p p a v a r i a n t S p r o t e i n e x h i b i t s a n o v e l d i m e r -o f -t r i m e r s p h e n o t y p e . ( A ) S i d e v i e w o f t h e g l o b a l c r y o -E M d e n s i t y m a p o f t h e K a p p a v a r i a n t d i m e r -o f -t r i m e r s c o m p l e x . O n e t r i m e r ( S P r o t e i n 1 , b o t t o m ) i s d i s p l a y e d i n v a r i o u s s h a d e s o f b l u e , a n d t h e o t h e r t r i m e r i n g r a y s c a l e ( S P r o t e i n 2 , t o p ) . n e d c r y o -E M d e n s i t y m a p a n d f i t t e d a t o m i c m o d e l a t t h e d i m e r i z a t i o n i n t e r f a c e . n i t i a l r e p o r t s o n K a p p a a n d D e l t a v a r i a n t a n t i b o d y e s c a p e 9 , 1 6 , 3 4 , 3 5 . I n t e r e s t i n g l y , a r e c e n t p r e p r i n t -w h i c h i n c l u d e s a l a r g e p a n e l o f v a c c i n e -i n d u c e d s e r a s a m p l e s -r e p o r t s g r e a t e r a n t i b o d y e v a s i o n f o r t h e K a p p a v a r i a n t s p i k e o v e r t h e D e l t a v a r i a n t 1 0 . T h e r e a r e s e v e r a l s i m i l a r o r i d e n t i c a l m u t a t i o n s c o m m o n b e t w e e n t h e K a p p a / D e l t a v a r i a n t s a n d p r e v i o u s l y e m e r g e d v a r i a n t s o f c o n c e r n ( A l p h a , B e t a , G a m m a , E p s i l o n ) . i g u r e 1 D ) . T h e r e f o r e , i t i s l i k e l y t h a t m u t a t i o n a l e f f e c t s t h a t i n f l u e n c e o t h e r a s p e c t s o f v i r a l f i t n e s s ( n o t a s s e s s e d i n t h e p r e s e n t p u b l i c a t i o n ) f u r t h e r r a t i o n a l i z e t h e u n i q u e c u r r e n t p r e v a l e n c e o f t h e D e l t a l i n e a g e . F o r e x a m p l e , t h e P 6 8 1 R m u t a t i o n -f o u n d i n a l l B . 1 . 6 1 7 s u b -l i n e a g e s -h a s r e c e n t l y b e e n r e p o r t e d t o e n h a n c e S p r o t e i n c l e a v a g e a n d c e l l -c e l l f u s i o n 1 1 , 1 5 , 3 5 . p r o t e i n s c o u l d r e s u l t i n i n c r e a s e d o r d e c r e a s e d v i r a l f i t n e s s . F i r s t l y , h e a d -t o -h e a d S p r o t e i n d i m e r i z a t i o n b u r i e s m u c h o f t h e a n t i b o d y -a c c e s s i b l e s u r f a c e a r e a o f t h e R B D ( t h e p r e d o m i n a n t t a r g e t o f n e u t r a l i z i n g a n t i b o d i e s ) a n d c o u l d s h i e l d t h i s o t h e r w i s e v u l n e r a b l e n e u t r a l i z a t i o n s i t e 1 3 . S e c o n d l y , d i m e r i z e d s p i k e s i n t h e s a m e m a n n e r a s r e p o r t e d f o r t h e K a p p a v a r i a n t -w o u l d b e u n a b l e t o e n g a g e t h e A C E 2 r e c e p f n e u t r a l i z a t i o n f o r t h e s e n a n o b o d i e s r e m a i n s u n c l e a r , t h i s m a y s u g g e s t t h a t S p r o t e i n d i m e r i z a t i o n h a s n e g a t i v e i m p a c t s o n v i r a l f i t n e s s . F u r t h e r s t u d i e s t o e l u c i d a t e t h e b i o l o g i c a l i m p l i c a t i o n s , i f a n y , o f t h i s d i m e r i z a t i o n p h e n o m e n o n a r e t h e r e f o r e h i g h l y r e l e v a n t i n t h e r a p i d l y e v o l v i n g S A R S -C o V -2 v a r i a n t l a n d s c a p e . 1 3 A c k n o w l e d g m e n t s T h i s w o r k w a s s u p p o r t e d b y a w a r d s t o S . S . f r o m a C a n a d a E x c e l l e n c e R e s e a r c h C h a i r A w a r d , t h e V G H F o u n d a t i o n , G e n o m e B C , C a n a p a c k a g i n g s y s t e m w a s u t i l i z e d i n c o m b i n a t i o n w i t h p l a s m i d s e n c o d i n g t h e f u l l -l e n g t h S A R S -C o V -2 s p i k e , a l o n g w i t h a t r a n s f e r p l a s m i d e n c o d i n g l u c i f e r a s e a n d G F P a s a d u a l r e p o r t e r g e n e . P s e u d o v i r u s e s w e r e h a r v e s t e d 6 0 h a f t e r t r a n s f e c t i o n , f i l t e r e d w i t h a 0 . 4 5 µ m P E S f i l t e r , a n d f r o z e n . F o r n e u t r a l i z a t i o n a s s a y s , H E K 2 9 3 T -A C E 2 -T M P R S S 2 c e l l s 5 0 ( B E I R e s o u r c e s c a t # N R -5 5 2 9 3 ( 2 0 m M T r i s p H 8 . 0 , 1 5 0 m M N a C l ) . P e a k f r a c t i o n s c o r r e s p o n d i n g t o s o l u b l e p r o t e i n w e r e p o o l e d a n d c o n c e n t r a t e d t o 8 -2 0 m g / m L ( A m i c o n U l t r a 1 0 k D a c u t o f f , M i l l i p o r e S i g m a ) . P r o t e i n s a m p l e s w e r e s t o r e d a t 4 ° C u n t i l u s e . E l e c t r o n M i c r o s c o p y S a m p l e P r e p a r a t i o n a n d D a t a C o l l e c t i o Data, disease and diplomacy: GISAID's innovative contribution to global health Global initiative on sharing all influenza data -from vision to reality Karthik Gangavarapu, Laura D. Hughes, and the Center for Viral Systems Biology. outbreak.info The-World-Health-Organization. Tracking SARS-CoV-2 variants Air travel-related outbreak of multiple SARS-CoV-2 variants. medRxiv, 2021 Transmission event of SARS-CoV-2 Delta variant reveals multiple vaccine breakthrough infections. medRxiv Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization Molecular basis of immune evasion by the delta and kappa SARS-CoV-2 variants. bioRxiv SARS-CoV-2 spike P681R mutation, a hallmark of the Delta variant, enhances viral fusogenicity and pathogenicity. bioRxiv Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2 An NTD supersite of attack Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant. bioRxiv SARS-CoV-2 B.1.617.2 Delta variant replication, sensitivity to neutralising antibodies and vaccine breakthrough. bioRxiv Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection High Potency of a Bivalent Human VH Domain in SARS-CoV-2 Animal Models A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2 Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody Structural Analysis of Receptor Binding Domain Mutations in SARS-CoV-2 Variants of Concern that Modulate ACE2 and Antibody Binding. bioRxiv Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity RBD Mutant Manuscript for Structural Evaluation of the Spike Glycoprotein Variants on SARS-CoV-2 Transmission and Immune Evasion Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity. The Lancet Infectious Diseases Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera SARS-CoV-2 variants, spike mutations and immune escape SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape Antibody-mediated neutralization of authentic SARS-CoV-2 B.1.617 variants harboring L452R and T478K/E484Q. medRxiv Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity Effect of SARS-CoV-2 B.1.1.7 mutations on spike protein structure and function Evolutionary analysis of the Delta and Delta Plus variants of the SARS-CoV-2 viruses Comparison of Neutralizing Antibody Titers Elicited by mRNA and Adenoviral Vector Vaccine against SARS-CoV-2 Variants Viral infection and transmission in a large, well-traced outbreak caused by the SARS-CoV-2 Delta variant SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes Structure-based design of prefusion-stabilized SARS-CoV-2 spikes UCSF Chimera-A visualization system for exploratory research and analysis Implementation of a Bayesian approach to cryo-EM structure determination SPHIRE-crYOLO is a fast and accurate fully automated particle picker for cryo-EM cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2 High resolution single particle refinement in EMAN2 Features and development ofCoot New tools for the analysis and validation of cryo-EM maps and atomic models MolProbity: all-atom structure validation for macromolecular crystallography Meeting modern challenges in visualization and analysis